drugset / Trial / NCT03920540
A Study of GC1111 in Hunter Syndrom Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this study is to evaluate the efficacy of GC1111 in Hunter Syndrome Patients
Timeline
- Start
- 2017-03-09
- Primary completion
- 2022-02-15
- Completion
- 2022-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC1111 | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |